Myriad Genetics, Inc. MYGN reported third-quarter 2024 adjusted earnings of 6 cents per share, which beat the Zacks Consensus Estimate of 2 cents. The company reported a loss of 3 cents per share in ...
(“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are ... it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic ...
BURLINGTON - Azenta, Inc., a life science company at 200 Summit Dr. in Burlington, recently announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta ...
Kevin Lynn Capps' remains were identified after over 32 years. His identity remained a mystery after his body was found burned in an abandoned boat in a field in 1992, the Weber County Sheriff's ...